Epidemiology and Clinical Features of Mpox in Jakarta, Indonesia, August 2022–December 2023
Penulis: Nilasari, Hanny; Miranda, Eliza; Marissa, Melani; Ruspitawati, Ani; Handayani, Dwi O. T. L.
Informasi
JurnalVaccines
PenerbitMultidisciplinary Digital Publishing Institute (MDPI)
Volume & EdisiVol. 13,Edisi 3
Halaman -
Tahun Publikasi2025
ISSN2076393X
Jenis SumberScopus
Sitasi
Scopus: 2
Google Scholar: 2
PubMed: 2
Abstrak
Background/Objective: This study explores the epidemiology and clinical features of re-emerging mpox in Jakarta, Indonesia. Methods: This study used a retrospective study design to describe the epidemiological data, clinical features, and mortality of mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both the epidemiology and clinical features of mpox in people living with HIV (PLHIV) and in non-HIV patients (non-PLHIV). Results: Our study shows that, as of the end of December 2023, 59 mpox cases were treated in Jakarta. All of the mpox cases in Jakarta were diagnosed in males, mainly found in MSM (91.5%), and PLHIV (78%). Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group (22/59, 37.2%). Severe manifestations were found among PLHIV without antiretroviral therapy (ART). Conclusions: Mpox cases in Jakarta were all found in males and most of them were PLHIV. There are various manifestations of mpox; however, since immunosuppressed patients could present differently, a strong surveillance and vaccine notification system, cautious management, and spreading vaccination awareness are needed to prevent and treat mpox. © 2025 by the authors.
Dokumen & Tautan
